Replies to post #41181 on Biotech Values

[Deadb440]

I've been in MPH for 3.5 years.
Avg. Price $1.99 and hold 30k shares.

I've spent Hundreds of hours researching this company and I don't mean time spent on Message Boards.

I've seen Friesen on atleast 2 occasions make misleading statements relative to timelines because he himself refered to a fiscal year whereas he ment a calander year or vise versa and not correct himself though I knew the error because I follow it that closely.

Take for instance....

"Management stated in the Jan/12 CC that they anticipated the release of MEND II clinical data at the end of 1st qtr 2008 and submission of an NDA in June/08. Most Phase III trials take 3yrs. MCU started enrollment in Nov/06 and anticipates submission of an NDA in Jun/08, 18 months."

The end of Fiscal first quarter of yr 2008 is actually the end of August and is in fiscal yr.09, so without the analysis completed they cannot submit a NDA in JUNE of ,08.

I spoke with Hogan Mullally in person at MPH headquarters and he explained that if the Ph2 trial took 6 months to analyse for 900 patients that we should expect atleast 9 months to complete the analysis this time around. Dr.Friesen always states his "Wish" for a timeline but has NEVER met it.

I'm very bullish but perturbed at the length's Dr.Friesen goes to outright mislead investors and though the science is perfect his management skills are likely just stretched way too thin since he's directly involved with 3 or four other companies that he's founded...

[daved]

Re fast track status trade said:

"Fast track status has nothing to do with an expedited review process once the NDA is submitted unless the FDA has also granted them priority review."

Isn't that a bit of an overstatement. Doesn't fast track, in and of itself, usually produce a faster review process?

Dave